Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Qianhai Health Holdings Limited (0911.HK)
Sheung Wan, HK
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Care Products and Electronic Component Products. The Health-Care Products segment supplies a range of items, including Chinese herbal medicines, various skincare and wellness products, and American ginseng, catering to both wholesale and retail clients. Concurrently, the Electronic Component Products division deals in items such as central processing units (CPUs) and semiconductors. Beyond these primary sales, the company also engages in the trading of both its health-care and electronic component offerings, alongside a money lending business. Established in 1989, the company underwent a name change in September 2016 from its previous identity, Hang Fat Ginseng Holdings Company Limited. It is headquartered in Sheung Wan, Hong Kong, and operates as a subsidiary of Explorer Rosy Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +19.05% | +2.74% | -21.05% | +163.16% | +172.73% | +172.73% | +290.63% | +33.93% | -39.02% | -96.93% | -98.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+30.3% ★ Q4'25: -45.9% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+355.8% ★ Q4'25: -98.0% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.1% ★ Q4'25: +10.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.8% Q4'25: +0.3% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.7% Q4'25: +1.1% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.06× ★ Q4'25: 0.06× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 2/5 | 3/5 | 4/5 | 3/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chee Lap Yuen | Executive Director | 1M | male |
| Yu Yuan Tang | Executive Director | 1M | male |
| Kwai Fong Ip | Financial Controller | — | female |
| Tak Yung Yip | Chief Financial Officer & Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0911.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
